Telehealth Prescribing Rules in 2026: Controlled Substances, DEA Registration, and the Pharmacy’s Role
An electronic prescription issued via a telehealth visit looks like any other prescription in the queue. For non-controlled substances, the status quo is kosher in most instances. Controlled substances are the exception. The federal framework that has allowed telehealth prescribing of controlled substances since 2020 is running on its 4th temporary extension. A permanent rule is under final review in Washington. Each state carries its own layer on top. Understanding how those pieces fit is worth doing now while the question is still hypothetical for most practices and pharmacies.
The federal layer
The starting point is the Ryan Haight Act of 2008, which generally requires a practitioner to conduct at least 1 in-person medical evaluation before prescribing a controlled substance by means of the internet, with exceptions that include the practice of telemedicine as the statute defines it. In March 2020, the public health emergency triggered an existing statutory exception to the in-person requirement. The DEA has kept that flexibility alive ever since through a series of temporary extensions. The current one took effect January 1, 2026, and runs through December 31, 2026. Under relaxed rules, a DEA-registered practitioner may prescribe Schedule II through V controlled substances through an audio-video telehealth encounter without a prior in-person evaluation.
What replaces the extension is the open question. In January 2025, the DEA proposed a special registration framework with 3 categories of registration for telehealth practitioners and platforms, and the agency received more than 6,400 public comments. In late August 2026, the DEA reportedly sent a final rule to the White House for regulatory review, with final action anticipated in November. The contents are not public, so anything built around the 2025 proposal may need revisiting once the final version is published. In the meantime, a practitioner prescribing controlled substances by telehealth still needs a DEA registration and authority in the state where the patient is located.
The state layer
In Tennessee, a provider delivering care through telehealth is held to the same standard of professional practice as a provider delivering the same care in person. Licensing boards may not set a more restrictive standard for telehealth than the provider’s practice act allows. The governing authority does contain exceptions. Every state has its own version, and the patient’s location, not the prescriber’s, is generally what decides which state’s law applies.
The pharmacy’s role
Under federal law, the pharmacist who fills a controlled substance prescription shares corresponding responsibility for its legitimacy with the practitioner who wrote it. That corresponding responsibility does not relax because the encounter happened over video. A telehealth prescription simply arrives with less context than other prescriptions. A telehealth prescription needs its own special analysis: whether the prescriber is licensed where the patient sits, whether the encounter met that state’s standard for a valid patient relationship, and whether the arrangement behind the platform would hold up if anyone examined it. When regulators review a telehealth pipeline, the pharmacy filling the volume is often the most visible licensee in it.
The DEA extensions are a bit like scaffolding around a building that is still going up. It holds, and people work on it every day, but it is worth knowing which parts are permanent before deciding how much weight to put on them. That is why the pharmacies and practices that handle telehealth volume well tend to have their approach written down: what they verify, what they document, and when a prescription gets a second look.
What to do now
Telehealth is now baked into the delivery of healthcare. Telehealth is how a growing share of patients get care, and the pharmacies and providers that handle that volume well are providing real access. The rules are moving, federal and state both, and the time to settle a written approach is before the final rule lands.
RxLaw Group helps pharmacies, prescribers, and telehealth practices evaluate their controlled substance prescribing and dispensing practices, review platform and vendor arrangements, and prepare for the rule changes ahead. The practice is led by Matt Gibbs, who spent more than 11 years inside Tennessee’s healthcare regulatory system. Schedule a free call to talk through how your telehealth workflow holds up.